Whitney Tilson is the founder and Managing Partner of Kase Capital Management, which manages three value-oriented hedge funds. Mr. Tilson is also the co-founder of Value Investor Insight, an investment newsletter.
Mr. Tilson has co-authored two books, The Art of Value Investing: How the World's Best Investors Beat the Market (2013) and More Mortgage Meltdown: 6 Ways to Profit in These Bad Times (2009), was one of the authors of Poor Charlie’s Almanack, the definitive book on Berkshire Hathaway Vice Chairman Charlie Munger, and has written for Forbes, the Financial Times, Kiplinger’s, the Motley Fool and TheStreet.com. He was featured in two 60 Minutes segments in December 2008 about the housing crisis (which won an Emmy) and in March 2015 about Lumber Liquidators. He served for two years on the Board of Directors of Cutter & Buck, which designs and markets upscale sportswear, until the company was sold in early 2007.
Mr. Tilson received an MBA with High Distinction from the Harvard Business School, where he was elected a Baker Scholar (top 5% of class), and graduated magna cum laude from Harvard College, with a bachelor’s degree in Government.
Mr. Tilson spent much of his childhood in Tanzania and Nicaragua (his parents are both educators, were among the first couples to meet and marry in the Peace Corps, and have retired in Kenya). Consequently, Mr. Tilson is involved with a number of charities focused on education reform and Africa. For his philanthropic work, he received the 2008 John C. Whitehead Social Enterprise Award from the Harvard Business School Club of Greater New York. He is a member and past Chairman of the Manhattan chapter of the Young Presidents’ Organization. Mr. Tilson lives in Manhattan with his wife and three teenage daughters.
Who I Am: I'm a retired individual investor. I retired at the end of 2013 after a 35 year career as a professor and research scientist at a major research university. So -- a career as a researcher and an educator, which is what I hope to continue here. Virtually every good teacher I've ever known says some version of "I learn more from teaching than my students do." There's a lot of truth in that, enough that there's an underlying selfish motivation for my writing here as I continue to learn about investing.
My professional life involved multiple international projects and collaborations, so I traveled extensively over those 35 years. I plan to continue doing so in my retirement. One consequence is that I'm liable to disappear from the site for extended periods. How can you miss me if I don't go away?
My investing priorities are building and refining portfolios designed to provide income and capital growth: Income for my retirement needs, and capital growth for my estate. My investing interests are tax-advantaged income from a range of sources, portfolio strategies, information- and bio-technology, and momentum-based strategic allocation.
Why I Write for Seeking Alpha: I learned long ago that "writing is nature's way of letting you know how sloppy your thinking is." The line comes from a Guindon comic strip of many years ago, and could not be more true in my case. When I did research professionally, I learned that writing it up forces me to think about details I might otherwise overlook. It's how I spent my working career, so it comes more or less naturally to me. I consider it an essential part of doing any research. So, the writing I do here is as much for myself as for the reader. As I started to contribute articles here, they grew out of research for my personal investment portfolios. They're based on things I've uncovered that are of interest to me and may be of interest to others of like mind. My primary purposes in writing them are to help clarify my thinking and to get feedback from others who may have very different opinions. It's those thoughtful comments that make Seeking Alpha such an important resource.
I try to actively engage myself in the comment streams in my articles, contributing what I can and learning from others. As a research scientist I spent a career spanning four decades devoted to free exchange of information vetted by rigorous peer review. It's a concept I firmly believe in. I hope to bring that approach to my interactions and contributions on Seeking Alpha and welcome critical commentary on anything I may contribute here. I especially encourage and appreciate thoughtful comments from those who disagree with me (although I will ignore obvious trolls and encourage others to do so as well). So, go ahead, start a conversation in the comment threads. It's one of the best things about Seeking Alpha.
My Investment Philosophies and Strategies: I maintain two portfolios. My income portfolio is a taxable account. I try to keep it separate from the growth portfolio which is housed in a series of IRAs, traditional and Roth. My income focus is on tax-advantaged income. In 2016 I face minimum required withdrawals from my tax-deferred accounts, so tax efficiency is an important consideration. The IRAs I see as my estate and are focused on generational wealth building. That means the growth portfolios have a long-term horizon, well beyond what an investor of my age might be expected to maintain.
Who Is Left Banker? Ah yes, the name. When I first joined Seeking Alpha I had no intention of being anything but an occasional reader. I saw it as another research site. So, I just ported a name I've used on other sites. I spent some of the best times of my life living on the left bank of the Seine and am always thrilled to be back in La Belle Paris. Add that I also like it because I find several subtle word plays there; I'll leave it to you to decipher that comment.
Finally, I've chosen to remain anonymous, which I feel obligated to justify. First, I have no professional role in finance and nothing to sell, so there is no advantage to be gained by "making a name for myself' here. Second, I value my privacy and have kept my internet presence as low-key as my professional life allowed. I certainly want to avoid any possibility of some internet connection trying to track me down. Odds against that happening are, of course, outrageously long, but why take them on at all?
Disclosures: I have no ties to the financial or security industries in any form. My interests are strictly personal. The banker part of the nym has absolutely no relationship to the profession of the same name. Readers should be aware that I am an investing novice, some might say dilettante. I do not give advice; what I publish is much more in line with a research notebook. Anyone who finds anything of interest will necessarily want to do his or her complete research and due diligence. It would be foolish to rely on my conclusions without having done so.
Brian is the founder of Investor in the Family and Online Investor Conference.
At Investor in the Family (http://investorinthefamily.com/), Brian's goal is to help protect investors from making big mistakes that jeopardize their portfolios and financial futures.
The Online Investing Conference (http://onlineinvestingconference.com/) was created to help link self-directed investors with carefully filtered and proven investing professionals to help save investors both time and money while building a portfolio that outperforms.
If you'd like to connect or learn more, please feel free to send a private message via Seeking Alpha platform.
Simply Safe Dividends helps conservative dividend investors increase current income, make better investment decisions, and avoid risk. Brian Bollinger, CPA, runs Simply Safe Dividends and previously worked as an equity research analyst at a multibillion-dollar investment firm.
Chartered Financial Consultant (CHFC) The American College
Chartered Life Underwriter (CLU) The American College
Master's Degree in Financial Sciences MSFS) The American College.
1976 - 1979 Regional Field Representative - GE Credit Corporation
1979 - 1991 Capital Analysts, Inc.
1991 - Founder, President, The Stanley-Laman Group, Ltd.,
2003 - Founder, Manager Stanley-Laman Securities, a Broker-Dealer
American Realty Capital Trust, Inc. (ARCT; NASDQ) - Independent Director, 2007 – 2012
New York REIT (NYRT; NYSE) - Director & Lead Independent Director, 2009 - 2014
Business Development Company of America - Independent Director
2009 - 2014
American Realty Capital Properties Retail Centers of America – Independent Director 2011- 2014
American Realty Capital Properties, IV - Lead Independent Director
2013 - 2014
American Realty Capital Properties, Inc. (ARCP; NYSE)
Interim Chairman and CEO 1-1-15 - 4/1/15
Lead Independent Director 1-1-14 - 1-1-15
Matrix Biology Institute - Trustee 2008 - Current
CeeLite, Inc., - Director 2008 - Current
Darren owns ProActive Financial LLC where he provides Financial Planning and Analysis consulting services. Darren's education includes a Bachelors in Economics, an MBA, and a Certificate in Personal Financial Planning.
Wall Street Breakfast, Seeking Alpha's flagship daily business news summary, is a one-page summary that gives you a rapid overview of the day's key financial news. It's designed for easy readability on the site or by email (including on mobile devices), and is published before 7:00 AM ET every market day.
Wall Street Breakfast readership of over 900,000 includes many from the investment-banking and fund-management industries.
Sign up here to receive the Wall Street Breakfast in your inbox every business day: http://seekingalpha.com/account/email_preferences
The Culverhouse Investment Management Group (CIMG) is a long-only value investment fund managed by select students at The University of Alabama with oversight from an investment consultant and faculty advisors. In January 2009, The University of Alabama Culverhouse College of Commerce established CIMG to give undergraduate students real-world portfolio management experience. The portfolio was funded with donations totaling $315,000 from Culverhouse College of Commerce alumni, with the group making its initial investment in October of 2009. For more information about CIMG please visit our website: http://mycba.ua.edu/cimg.
Professionally, I have done a bit of everything in my long life, from playing rock and roll, to developing software, and running a successful entrepreneurial business. But I am best known as a writer of bestselling books about business and health. I write under a pseudonym here on Seeking Alpha because that way I know readers will evaluate my work strictly on the basis of what I actually said rather than who I am.
I am a retired global analyst, currently busy in investing and writing articles about stocks at several investing publications and websites. I have also developed strategies for creating winning portfolios according to specific formulas.
In January 2015, I was ranked among the world’s top 10 financial bloggers according to TipRanks, which holds financial experts accountable for their recommendations by disclosing their stock ratings since 2009:
GE (NYSE: GE) works on things that matter. The best people and the best technologies taking on the toughest challenges. Finding solutions in energy, health and home, transportation and finance. Building, powering, moving and curing the world. Not just imagining. Doing. GE works. For more information, visit the company's website at www.ge.com.
I'm a capital projects manager and process design engineer at a large-cap biotech company. I love the financial world because it is like one big puzzle and I hope we the Seeking Alpha Community help each other out to solve the puzzle to help us realize our dreams.
Individual investor focused upon a limited number of diversified stocks. Seeks stocks selling below fair value; favors dividend growth. Advocates fundamental investment analysis, supplemented by the technical charts. Options strategies primarily employed to generate additional income or hedge risk.
You can follow me on Twitter and StockTwits, just search Nathan Buehler.
I have always had a passion for finance and investing. I enjoy and appreciate engaging with like minded individuals that inspire me to think beyond what is generally accepted. My investment experience spans almost ten years. The bulk of my knowledge has come from independent observation, research, patience, and perseverance. Most of my strategy is geared towards long term outlook with focuses on short term events or situations that create attractive opportunities.
I hope the articles presented here help you in your investment decisions. I value our discussions and look forward to professional dialogues. If I can ever help you with anything please contact me. Know you are always going to get a straight answer. If I don't know the answer I will either research it for you or tell you I don't know.
During the school year there may be a delay in my responses. Keep the feedback coming!
My name is Phil Mause. I am a Senior Advisor with the Pacific Economics Group, focusing on energy, regulatory and valuation issues. I retired from 40 years of law practice earlier this year. I am a yield oriented investor and in the last two years, I have done reasonably well in junk bonds, BDCs, mortgage REITS, and dividend paying blue chip stocks. As an avocation, I dabble in stand up comedy.
Investor, author, blogger and mentor, James helps others build long-term wealth through the investment markets.
James is a global senior investment analyst whose considerable experience spans three continents; North America, Europe and Australia.
He is also the best selling author of The Brooks Way: Compound Wealth and Protect Capital in Equity Markets.
GuruFundPicks.com offers top buy & sell picks based on the collective or Consensus Picks' of over 330 of our hand-picked top hedge & mutual fund managers, incl. 78 legendary or guru fund managers, 27 of the world's largest or mega funds, 165 sector-focused funds (in gold, biotech, tech, energy, consumer, finance & REITs), 59 billionaires, 54 new masters and 40 tiger, 52 shareholder activist and our Winners Circle Top 100 Performing Hedge Fund Managers (updated quarterly). We offer market-beating tools and services including Consensus Picks' DIY Tools, Top 20 Small-Cap and Top 30 All-Cap Long/Short Newsletters based on the Consensus Picks system, and Trade Alert Services for Self & Auto-Trading. All of our services have beaten market averages by wide margins. See our website GuruFundPicks.com for the latest performance numbers, or contact us at support@GuruFundPicks.com.
The two authors are co-managers of a family partnership long/short equity fund since 2001, that have a successful track record in trading primarily small-cap aggressive growth companies based on a fundamental valuation analysis of current news, including quarter reports, guidance, biotech clinical study results and other news. The junior partner is a self-taught private investor with a Business degree from the New York University's Leonard N. Stern School of Business and the senior partner has an MBA from the University of Virginia Darden School of Business, including prior MS & BS (Engg.) degrees, and with experience in business strategy consulting to large fortune 100 companies.
We are generally sector and market-cap agnostic, identifying opportunities using a 'stock picking' bottom-up, fundamentals-based, valuation-driven approach. However, we find most opportunities in the small-cap space, in technology & healthcare sectors, with some also found often in the consumer, energy & basic materials sectors.
Follow us on Seeking Alpha and Twitter (@GuruFundPicks), and connect with us on LinkedIn (http://www.linkedin.com/in/manishbabla)
Francesco is a Financial Economist educated in Florence and London (Cass Business School).
He obtained the Investment Management Certificate and the Chartered Financial Analyst (CFA) qualification.
After some years in the City of London and Paris, where he worked among others for Morgan Stanley and Moody's, he decided to go back to his native Tuscany, where he works as a consultant.
He is a martial arts expert (II Dan Judo black belt and kickboxer). Besides Italian, he speaks English, French and Spanish fluently and understands Czech and German.
From high school he remembers Latin well and Ancient Greek badly, though he still can read the latter.
I have a diverse background—as a financial journalist, resident physician, mixed martial artist, painter, entrepreneur, chemistry instructor and web developer—that enabled me to pioneer the “Integrated Investing Research” approach.
I provide consulting to clients, both the retail and professional investors. I accurately forecasted many clinical trials, such as the Flint Trials for Intercept, the Ascend Trials for InterMune and the Affinity Trials MannKind, just to name a few. Through Vincata Enterprises, LLC, I helped many clients to unlock substantial values for their investments.
As an expert in biopharmaceutical analysis, I am also more than capable of analyzing any other industries. Though not shown on Seeking Alpha, I have picked an aggregate basket of outperforming stocks.
Investing in biotech is highly risky, but it can be quite rewarding when investors have an edge in data analysis. Physicians who are rigidly scientific tend to lack the analytical prowess of financial experts. Conversely, financiers usually do not possess a physician’s medical expertise. Likewise, scientists are skillful in data analysis; yet they might not be familiar with a physician’s prescribing patterns, which is a requisite to successful biotech investing.
You can visit my website at https://www.retailinvestor360.com for business inquiry.
I'm a radiologist by trade, but the goal is to leverage that medical knowledge as a competitive advantage in the markets. I aim to include all of the following in my analyses to ensure high quality: 1) quantitative estimates; 2) new information or inferences that are not already disseminated throughout the market; and 3) hypotheses that are testable, i.e. can be proved right or wrong. I have a serious allergy to question marks and will never, ever include one in an article title.
My dream is to co-found a biotech and bring a cure from the lab to the bedside. In the meantime, saving lives in clinical practice is a perfectly acceptable alternative.
Please note that all opinions I express on this website reflect my personal beliefs only and are completely independent of my current or past employers and/or affiliated institutions.
Earned a Doctorate in Pharmacy (Pharm.D.) in 2010 and Pre-Pharmacy/B.S. in Molecular Biology in 2006. Over six years of direct experience in translational research in oncology investigating the molecular/cellular mechanisms of carcinogenesis focused on biomarker identification and validation working in a multi-disciplinary matrix environment across academia, contract research organizations and industry.
Analyst Tip Ranks: https://www.tipranks.com/experts/dr.-paul-nunzio-desantis%252C-pharm.d
Stephen Simpson, CFA, is a freelance financial writer and investor.
I have worked for both sell-side and buy-side firms (equities and fixed income), with the largest percentage of my working time spent in med-tech. At this point I am now effectively in a "working retirement".
I write because I find that the process helps me take better notes, be more disciplined about modeling, and come up with a more coherent investment view for my portfolio management needs. If I'm writing about a stock, it's generally because I'm interested in it as an investment prospect or I think there's an interesting story to tell.
I don't share my models, so please don't ask.
More of my writings can be found at my blog Kratisto Investing (kratistoinvesting.blogspot.com), or Twitter (@Kratisto_Invest).
Jeff is the President of NewArc Investments Inc., manager of both individual and institutional investments. Jeff is a registered investment advisor, and portfolio manager for NewArc's investment programs. Jeff is a former college professor with a hands-on, real world attitude. His quantitative modeling helped inform state and local officials in Wisconsin for more than a decade. A Public Policy analyst, he taught advanced research methods at the University of Wisconsin, and analyzed many issues related to state tax policy. Jeff began in the financial business as Research Director for trading firm at the Chicago Board Options Exchange. He investigated anomalies in the standard option pricing models, taught classes for beginning options traders, and developed new forecasting techniques. In 1991 he established a general research consultancy, working with professional traders at all of the Chicago financial exchanges. In 1998 he started NewArc Investments, Inc. Jeff has a commitment to the specific needs of individual investors. It is not a one-size-fits all approach, but one that emphasizes the unique circumstances of each client. Jeff also serves on the board of two small technology companies (currently Chairman at one). He is occasionally as an expert witness in legal cases involving financial markets and hedging.
CFA Institute is a global community of more than 100,000 investment professionals working to build an investment industry where investors’ interests come first, financial markets function at their best, and economies grow.
Investor. Mission: Help people make money. Degree: Chemistry from NC State University. Featured author of Momentum Options Weekly Wrap (http://momentumoptionstrading.com/ )
Follow me on Motley Fool Caps at http://caps.fool.com/player/modestus1.aspx .
For short-term ideas about big movers, follow my StockTalks. But please note I am not the best short term stock picker. I am 7-0-1 in the long term, but 0-3 in the short term. If you want better short term pickers, I recommend Michael Filloon and Alfred Little.
Over the last 12 years, I am 7-4-1. I was up 130%, 29%, 15%, 3%, 19%, 25%, 56% from 2001-2007 respectively, and down 39%, 39%, 79% from 2008-2010 respectively. In 2011, I was flat, but some ill-timed trades (should have held AG) caused a loss of 17% and 14% in 2012 and 2013. Note: gains and losses include transaction costs. 2009 and 2010, I traded frequently, adding up transaction costs. That is why I favor longterm holding over shortterm trading.
I invest in all stocks. I don't agree that US stocks are the safest. Want a safe stock, try TEVA. It did not fall much, or at all, during the credit crisis. And generics are the future.
Being a chemistry graduate, I tend to focus of the drug, medical, biotech, and chemical industries. So far, I wrote about 5 medical companies (RPC, OREX, KV.A, PLX, & XOMA). OREX and KV.A were right on target, though KV.A has fallen back hard after reaching their highs, which surprised me. PLX was half right: it did get a negative letter from the FDA, but the options strategy was wrong. For RPC, so far, I have been wrong, and exited my position in mid-May. XOMA also has fallen since I wrote about it.
However, I also cover diverse stocks, from BIDU to NCT. Ignoring other industries is a big mistake. I look for stocks I find undervalued on both a value perspective and a growth perspective, but placing more emphasis on growth. I combine both fundamental and technical analysis. The fundamentals only tell you part of the story.
Anybody can make money. Don't let Wall Street analysts manipulate you. Their analysis is good, but don't take everything they say. Good luck investing, and I will do everything I can to make you money.
Oh, and I invest in rather risky stocks with high potentials. If you are nearing retirement, I don't recommend you copy my portfolio. I will label my stocks with the risk/reward factor. I am adding a watch list with some stocks for retirement investors that I like. All watch list stocks are long term holdings.
BRK.B (very low risk/medium reward)
NRZ (medium risk/medium reward)
EXK (medium risk/medium reward)
SNR (medium risk/medium reward)
NCT (medium risk/high reward)
HOV (medium risk/high reward)
FRO (medium risk/high reward)
AMD (medium risk/high reward)
RGSE (very high risk/high reward)
SUNE (extremely high risk/very high reward)
AG (medium risk/medium reward)
YRCW (very high risk/very high reward)
GTIM (medium risk/high reward)
BOJA (medium risk/high reward)CVRR (medium risk/high reward)SWKS (medium risk/high reward)JAZZ (medium risk/high reward)NFLX (medium risk/high reward)
LVS (medium risk/high reward)
SAM (medium risk/high reward)
CMG (medium risk/high reward)
ZNH (medium risk/high reward)
RDY (medium risk/high reward)
MNK (medium risk/high reward)
YZC (low risk/high reward)
AVGO (low risk/medium reward)
CF (low risk/high reward)TTM (low risk/high reward)
NVO (low risk/high reward)
BIDU (low risk/high reward)
PCLN (low risk/high reward)
CLF (low risk/medium reward)
AAPL (low risk/medium reward)
GOOG (low risk/medium reward)
TEVA (low risk/medium reward)
CIM (low risk/medium reward) - dividend stock
TNH (low risk/medium reward) - dividend stock
GOL (low risk/medium reward) - dividend stock
We are a research group that consults hedge fund and high-net worth clients. We specialized in identifying special opportunities from both the long and short side. The writer for 3D Analytics has professional traded for hedge funds for 10+ years and specializes in 1) finding hidden, unrecognized value, 2) shorting overvalued stocks, and 3) arbitrage situations. The articles are written solely by him, but has a group that assist him in finding opportunities, basic research, and editing.
I focus on writing about individual stocks, frequently in the financial industry. I work as a mid-level executive in the insurance industry on the portfolio management side. I'm an experienced stock investor, and I'm eager to share my industry expertise and what I've learned about investing with other Seeking Alpha users.
Dr. Thomas K. Carr (aka “Dr Stoxx”) is the Founder of DrStoxx.com (formerly “Befriend the Trend Trading”). He holds M.Phil. and D.Phil. degrees from the University of Oxford. For 16 years he was a tenured professor and department chair. He currently is a fulltime trader, market analyst, trading systems developer, and trainer of traders. His management company, Kingdom Capital (est. 2012), manages “The 8:18 Fund”.
Dr. Carr is author of two bestselling trading books: "Trend Trading for a Living" (McGraw-Hill, 2007) and "Micro-Trend Trading for Daily Income" (McGraw-Hill, 2010). They have been translated into Chinese, Japanese and Korean. His new book, "Market-Neutral Trading", was just published. Dr. Carr’s insights into the markets have been published in "The Wall Street Journal", "US News and World Report", "Investors Business Daily", and "Technical Analysis of Stocks and Commodities".
Price Headley was inducted into the Traders' Hall of Fame in 2007 and is the founder of BigTrends.com, which provides investors with specific real-time stock and options strategies and investment education to profit from significant market trends. Price appears regularly on CNBC, Fox News, and in a variety of major financial news outlets. Timer Digest recognized the success of BigTrends.com's investment strategies by ranking Price among the Top 10 Market Timers for stock market timing.